Document is current

Article History

Received: 24 November 2024

Accepted: 1 January 2025

First Online: 7 January 2025

Declarations

:

: TT has received honoraria from Bristol Myers Squibb (BMS), Janssen Pharmaceutical, Sanofi, Kyowa Kirin, and Chugai Pharmaceutical; TK has received honoraria from BMS, Chugai Pharmaceutical, Nippon Shinyaku, Ono Pharmaceutical, Sanofi, Nippon Kayaku, AstraZeneca, Abbvie, MSD, and Janssen Pharmaceutical; EK has received honoraria from Janssen Pharmaceutical, Chugai Pharmaceutical, Astra Zeneca, Alexion Pharmaceutical, BMS, Sanofi, Kyowa Kirin, Genmab, and Meiji Seika; NU has received honoraria from BMS, Janssen Pharmaceutical, and Abbvie; SF has received honoraria from Takeda Pharmaceutical, Sanofi, Janssen Pharmaceutical, Ono Pharmaceutical, and BMS; TF has received honoraria from Takeda Pharmaceutical; SM has received honoraria from Amgen, Astellas, Otsuka Pharmaceutical, Nippon Shinyaku, Chugai Pharmaceutical, Ono Pharmaceutical, Sanofi, and BMS; YS has received honoraria from Ono Pharmaceutical, BMS, Janssen Pharmaceutical, Sanofi, Kyowa Kirin, Takeda Pharmaceutical, and Chugai Pharmaceutical. JK is a consultant for Janssen Pharmaceutical, Pfizer, Abbvie, BeiGene, and BMS; has received research funding from Kyowa Kirin, Chugai Pharmaceutical, Asahikasei, Sumitomo Pharma, Otsuka Pharmaceutical, Mochida Pharmaceutical, Taiho Pharmaceutical, and Japan Blood Products Organization; and has received honoraria from Janssen Pharmaceutical, Kyowa Kirin, Chugai Pharmaceutical, Ono Pharmaceutical, Sanofi, Pfizer, Astra Zeneca, Astellas, Eisai, Abbvie, Novartis, Daiichi Sankyo, Amgen, Otsuka Pharmaceutical, and BMS. The other authors have no conflict of interest.

: The ethics committee of each participating institute approved the study. Under this approval, the need to obtain informed consent from the study subjects was waived, and we disclosed information about the survey to the patients.

: Not applicable.